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Objective: The current study assessed depressive symptoms in Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus 
(T2DM) patients and explored whether these symptoms were associated with glycemic control. Methods: A cross-sectional 
design was used. Patients attending diabetes consultations participated in the study (N = 347). Participants completed the Beck 
Depression Inventory (BDI), and glycemic control was based on A1C criteria. Results: The mean score on the BDI, for either T1DM 
or T2DM, was not clinically significant and was not associated with diagnosis duration. The association between depression and 
glycemic control was significant in both DM types. T2DM participants presenting more depressive symptoms were those with 
greater glycemic control. T1DM and T2DM differences regarding depressive symptoms were in somatic symptoms. Conclusions: 
In T2DM depressive symptoms may be confounded with DM physical consequences. There is also the possibility that negative 
mood plays a mediating role in mobilizing survival strategies that promote glycemic control. Furthermore, the assessment of 
depressive symptomatology in patients with diabetes could benefit from the availability of a disease-specific measure. 
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Resumo 
Objetivo: O presente estudo procurou avaliar a presença de sintomas depressivos em pacientes com diabetes mellitus tipo 1 
(T1DM) e tipo 2 (T2DM), explorando a sua associação com o controlo glicémico. Métodos: Estudo de desenho transversal. 
Participaram no estudo 347 pacientes com um diagnóstico de diabetes mellitus tipo 1 e tipo 2, os quais preencheram um 
questionário sociodemográfico e clínico e o Inventário Depressivo de Beck (BDI). Os valores do controlo glicémico foram 
facultados pelo clínico assistente, sendo baseados no critério de hemoglobina glicada (A1C).  Resultados: O score médio do BDI 
total para os pacientes com T1DM ou T2DM não se revelou clinicamente significativo e não se encontrou associado à duração da 
doença. A associação entre sintomas depressivos e controlo glicémico foi significativa em ambos os tipos de diabetes. Os 
pacientes com T2DM que apresentaram mais sintomas depressivos foram os que evidenciavam maior controlo glicémico. As 
diferenças observadas nos sintomas depressivos dos pacientes com T1DM e T2DM manifestaram-se nos sintomas somáticos 
avaliados pelo BDI. Conclusões: Os sintomas depressivos nos pacientes com T2DM podem ser confundidos com as consequências 
físicas da própria diabetes. De referir igualmente a possibilidade de o humor negativo desempenhar um papel mediador na 
mobilização das estratégias promotoras de um adequado controlo glicémico. 
 





Diabetes mellitus (DM) integrates a heterogeneous group of metabolic disorders characterized by the body's 
inability to maintain glucose homeostasis. In 2019, this public health problem affected 463 million adults, and 
this will rise to 700 million in 2045 (International Diabetes Federation, 2020). Furthermore, 30% to 80% of cases 
remain undiagnosed, this being a major challenge in public health (World Health Organization [WHO], 2011). 
Type 2 DM (T2DM) is the most common, being responsible for 95% or more of the total cases. It is closely 
associated with lifestyle factors (e.g., diet and physical activity levels). T2DM is has a higher prevalence among 
middle-aged and older individuals, although it is increasingly appearing in overweight children, adolescents, 
and young adults (WHO, 2016). T1DM is less prevalent (3-5% of all cases of DM) and affects children and young 
adults, particularly. T1DM is characterized by the pancreatic beta-cell mass destruction, being these cells 
responsible for producing insulin. Although not fully understood, the origin of T1DM seems to be related to an 
overaggressive autoimmune response, which leads to the failure of pancreatic endocrine function (Kahanovitz 
et al., 2017).  
There is consensus in the fact that that depression is commonly associated with chronic illnesses (e.g., 
Gonzalez et al., 2007; Park et al., 2004). Depression tends to appear as a comorbid condition in patients 
suffering from chronic diseases, as in the case of DM (Chireh & D'Arcy, 2019). It is common to observe an 
increase in symptomatology and medical costs, a decline in adherence to prescribed therapies, as well as a 
greater risk of morbidity and mortality (Son et al., 2011), specifically in terms of DM, a proportion of DM 
patients (20-40%) experience emotional difficulties, ranging from disorders specifically related to the disease 
to general symptoms of anxiety and depression (Son et al., 2011). Regarding depression, it constitutes not only 
a risk factor for the development of DM but is also a psychiatric condition highly prevalent in DM patients 
(WHO, 2003). Prospective studies with representative samples (1715, 2662, and 2764 individuals) showed that 
depression appears as a risk factor for the diagnosis of DM with a prevalence of 20% to 30% (Fráguas et al., 
2009). In a systematic review of the epidemiological aspects of depression, the prevalence of this mood 
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disorder in DM patients ranged from 0% to 60.5% (Moreira et al., 2003).  Independently of these mixed results, 
it is estimated that depression is two to four times higher in the DM population than in the healthy population 
(Silva, 2006). Moreover, the association between depressive symptoms and poor glycemic control (Guedes et 
al., 2016) and depression and diabetes complications (Nouwen et al., 2019) has been previously reported. 
Adherence to long-term therapies for patients in developed countries is expected to achieve 50%, whereas, 
for developing countries, it tends to exhibit a smaller percentage, given the lack of resources and inequality of 
access to health care (WHO, 2003). Some studies point to non-adherence rates ranging from 4% to 92%, stating 
that these rates usually vary between 30% and 60% (Masek & Janke, 1982).  The WHO study "The COst of 
Diabetes in Europe – Type 2 [CODE-2]" states that 28% of patients pursuing treatment for DM achieve glucose 
control (WHO, 2003). In the United States, less than 2% of DM adults carry out the ADA's highest 
recommended level of health care. These percentages are related to the fact that keeping DM under control 
requires more than simply taking medication (Costa et al., 2011; Fráguas et al., 2009; Guedes et al., 2016; 
Moreira et al., 2003; Silva, 2010; WHO, 2003). The literature reports that multiple factors influence a person's 
level of adherence to treatment. In addition to the precision associated with the administration of 
pharmacological therapies, patients are requested to engage in health promotion behaviors and, for most of 
them, to change their lifestyles. The centrality of the patient's role in self-administered health care 
management is a crucial topic. Adherence to treatment does not imply simply the scrupulous following of the 
medical regimen; it also entails engaging in several health-related behaviors, such as eating behaviors or 
physical activity (WHO, 2003). Indeed, DM implies the measurement of a wide range of intervening factors 
related to glycemic control. As the operationalization of these multiple factors is difficult, namely in terms of 
behavior, "results" are measured via what the evidence reports as predictors for care/practices for glycemic 
control – biochemical criteria provided by A1C testing (glycated hemoglobin testing). Therefore, A1C is used 
as a diagnostic and monitoring tool for glycemic control. These criteria can be influenced by multiple variables 
such as insulin sensitivity, an individual's physiological characteristics, and the efficiency of doctor-patient 
communication. Despite the limitations as mentioned above, the ADA recommends A1C as the best test to 
determine how well a patient's glycemia is under control.   
As for A1C levels, studies conducted by the Diabetes Control and Complications Trial  (DCCT) and by the 
United Kingdom Prospective Diabetes Study (UKPDS) have shown that the lower the A1C, the better the 
prognosis (International Diabetes Federation, 2017). Currently, the criterion of 'the lower the A1C levels, 
the better' is no longer widely accepted since values for A1C vary according to the patient, their age, and 
associated comorbidities. Therefore, the A1C recommended values by the ADA for young people without 
comorbidity is under 7%, and under 8% for older individuals suffering from complications. When these 
scores are exceeded, the DM patient will be considered as not having the disease under control, and, from 
a clinical point of view, probably, glycemic control is not occurring. 
The current study sought out to explore whether there were differences between T1DM and T2DM patients in 
terms of depressive symptoms, as well as the relationship between these symptoms and glycemic control, 
considering that depressive symptoms may influence the degree to which individuals engage in medical 
recommended procedures/behaviors. Moreover, the association of duration of the disease and depressive 
symptoms was also addressed. 
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This cross-sectional study included 347 individuals with a DM diagnosis (T1DM and T2DM) attending consultations 
at the Department of Endocrinology, Diabetes, and Metabolism of the Coimbra Hospital and University Centre 
(CHUC) and at the APDP – Diabetes Portugal (Portuguese Diabetes Patients Association). Inclusion criteria were 
age over 18 years old and a DM diagnosis for at least one year (the assisting doctor reported DM diagnosis). The 
current sample was a convenience sample. 
 
Instruments 
Sociodemographic questionnaire (SDQ). The SDQ included questions regarding age, sex, marital status, and years 
of education. Clinical data regarding A1C (metabolic control level) was also collected. 
Beck Depression Inventory (BDI; Beck et al., 1961; Portuguese version by Vaz-Serra & Pio-Abreu, 1973). The BDI 
is a widely used self-report measure of depressive symptoms composed of 21 groups of statements addressing 
affective, cognitive, motivational, delusional, physical, and functional (e.g., sleep pattern, weight loss, libido) 
symptoms. Data from the BDI validation study in the Portuguese population showed that scores between 0 and 9 
indicate the absence of depression, between 10 and 20 slight depressive states, between 21 and 30 moderate 
levels of depression and over 30 severe depression (Vaz-Serra & Pio-Abreu, 1973).  In the current study, the BDI 
Cronbach alpha was of .89. 
 
Procedures 
Participants' recruitment was carried out directly at the Department of Endocrinology, Diabetes, and Metabolism 
(CHUC) and the APDP, by healthcare professionals (physicians and psychologists) at the beginning of the 
consultation. Eighteen months was set for data collection. After receiving information regarding the study aims, 
the voluntary nature of their participation, as well as anonymity and confidentiality, participants gave their written 
informed consent and completed a set of self-report instruments (paper-pencil format). The Ethical Committee of 
the Coimbra Hospital and University Centre approved the study. 
 
Statistical analysis 
Data were analyzed using the IBM Software Statistical Package for Social Sciences (SPSS v.25). Independent 
samples t-tests were used for mean comparisons of continuous variables, and chi-square tests were used to 
compare frequencies. Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) for each level of each 
variable (in comparison with each variable's reference group) were analyzed. Pearson correlations were calculated 
as preliminary analysis for conducting multiple linear regression. Cohen's d effect sizes were computed. Pearson 
correlations were used to explore the association between duration of DM diagnosis and depressive symptoms, 
as well as A1C levels (A1C ≤ 7%). Assumptions for conducting statistical analyses were verified. 
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Results 
Table 1 presents the sociodemographic and clinical characteristics of participants. The two groups showed 
differences regarding age, with T2DM individuals being significantly older (M = 57.83; SD = 11.40; Cohen’s d = 
1.55), with ages ranging from 18 to 81 years old. Regarding A1C, there were also significant differences between 
T1DM (t = 2.40; p = .017; Cohen’s d = 0.26). T1DM participants presented higher A1C scores (M = 8.58; SD = 
1.47) when compared to T2DM (M = 8.19; SD = 1.52). 
 
Table 1 
Sociodemographic and Clinical Characteristics of the Participants 
 
T1DM 
(n = 159) 
 T2DM 
(n = 188) t (345) p 
 M SD  M SD 
Age 38.80 13.10  57.83 11.40 -14.47 < .001 
A1C 8.58 1.47  8.19 1.53 2.40 .017 
 n %  n %  2 p 
Gender      2.19 .139 
Men 83 52.2  113 60.1   
Women 76 47.8  75 39.9   
Marital status      61.00 < .001 
Single 57 35.8  16 8.6   
Married 85 53.4  139 74.4   
Divorced 16 10.0  20 10.7   
Widow 1 0.6  12 6.4   
Years of education      50.64 < .001 
1 – 4 8 5.1  51 27.3   
5 – 6 9 5.7  27 14.4   
7 – 9  20 12.7  29 15.5   
10 – 12 56 35.4  36 19.3   
Higher Education 65 41.1  44 23.5   
Note. A1C = Glycated hemoglobin test; T1DM = Type 1 diabetes mellitus; T2DM = Type 2 diabetes mellitus. Significant results are in bold.  
 
No differences were found between T1DM and T2DM groups in the BDI total score (t = -1.82; p = .070; Cohen’s d 
= 0.20). However, a more detailed analysis regarding the BDI items, showed statistically significant differences 
between T1DM and T2DM regarding symptoms of work difficulty score (t = -4.74; p < .001; Cohen’s d = 0.52), 
insomnia score (t = -2.21; p = .028; Cohen’s d = 0.24), fatigability score (t = -2.40; p = .017; Cohen’s d = 0.26), weight 
loss score (t = -2.08; p = .039; Cohen’s d = 0.22), and loss of libido score (t = -4.76; p < .001; Cohen’s d = 0.51). For 
these symptoms mean scores were higher in T2DM (Table 2). No other differences were found between T1DM 
and T2DM concerning the other BDI symptoms.  
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Table 2 
T1DM and T2DM Comparisons Regarding Depressive Symptoms (BDI, Beck Depression Inventory) 
Items  M SD t p 
BDI-15 
T1DM 0.43 0.72 
-4.74 < .001 
T2DM 0.89 1.00 
BDI-16 
T1DM 0.63 0.86 
-2.21 .028 
T2DM 0.86 1.04 
BDI-17 
T1DM 0.65 0.62 
-2.40 .017 
T2DM 0.81 0.62 
BDI-19 
T1DM 0.31 0.69 
-2.08 .039 
T2DM 0.49 0.90 
BDI-21 
T1DM 0.50 0.84 
-4.76 < .001 
T2DM 0.99 1.04 
Note. T1DM = Type 1 diabetes mellitus; T2DM = Type 2 diabetes mellitus. 
 
The association between depressive symptoms and glycemic control in T1DM patients was statistically significant 
(χ2 = 5.86; p = .015). T1DM patients showing no depressive symptoms show 5.4 times more glycemic control than 
those participants presenting depressive symptoms (OR = 5.4; IC95% = 1.20-24.21). As for T2DM, depressive 
symptoms were also associated with glycemic control (χ2 = 6.58; p = .010). T2DM participants showing depressive 
symptoms exhibit 2.5 times more glycemic control than those with T2DM showing no depressive symptoms (OR 
= 2.5; IC95% = 1.251-5.053). Associations between sex, age, marital status, years of education and glycemic control 
were also explored as preliminary analyses for conducting a multiple linear regression. Given that no significant 
associations were found (p > .05) the regression analysis was not performed. 
Finally, when considering the association of duration of the disease and depressive symptoms, no significant 
correlations were found for either T1DM (r = -0.07; p = .650; R2 = 0.49%), or T2DM (r = -0.02; p = .826; R2 = 0.04%). 
The same pattern was found for the correlation between the duration of DM diagnosis and glycemic control for 
T1DM (r = -0.17; p = .236; R2 = 2.89%), or T2DM (r = 0.08; p = .440; R2 = 0.64%). 
 
Discussion 
DM is a clinical condition with specific characteristics, even when compared with other chronic pathologies. 
Whereas T1DM implies that a patient will have earlier contact with the disease and its therapeutic demands, T2DM 
obliges individuals to undergo significant changes regarding both pharmacological treatment and lifestyle. These 
subsequent changes in behavior, such as eating habits and physical activity levels, may lead to emotional 
reactivity. Thus, the emotional impact when faced with a DM diagnosis and its treatment plan must be taken into 
account when attempting to achieve a more holistic approach. Common emotional reactions are anger, 
resentment, and depression, independently from the etiology and age group, leading to significant psychosocial 
changes (Santos Filho et al., 2008). Indeed, the relationship between depression and chronic diseases (Birk et al., 
2019), and depression and specifically DM has been frequently acknowledged in the literature (Cox & Gonder-
Frederick, 1992; Fráguas et al., 2009; Góis, 2013; Saraiva, 2014).  
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In the current study, when comparing the sociodemographic characteristics of participants presenting T1DM and 
T2DM, differences were found in terms of age, marital status, and years of education. These differences were 
somehow expected, given that the incidence of T2DM is higher for older age groups. Regarding the comparison 
of A1C, differences were also found between the groups, with T2DM patients showing more favorable glycemic 
control scores. This finding may be attributable to the fact that control of T2DM is easier to establish as the 
pancreas is still able to produce insulin; this not being the case in T1DM. 
Regarding the association between glycemic control and depressive symptoms in T1DM and T2DM, a significant 
relationship was found in both groups, which is in accordance to what has been reported in the literature (Egbuonu 
et al., 2019; Park et al., 2004; Picozzi & DeLuca, 2019; Santos et al., 2013). Nevertheless, in other studies, 
depressive symptoms and glycemic control did not show a clinically significant association (Braz et al., 2012; Fisher 
et al., 2007). Similarly, emotional factors such as depression were not associated in a significant way with DM 
glycemic control (Ramos & Ferreira, 2011; Silva et al., 2005). Although studies addressing the relationship between 
depressive symptoms and glycemic control in DM patients have produced mixed results, in the current study, 
differences were found between T1DM and T2DM patients. While these clinical conditions are manifestly 
different, the glycemic control criteria used were the same. 
Moreover, current study results were similar to the ones found in other studies for T1DM (Tovar et al., 2015); for 
T2DM, they were in the opposite direction (Mansori et al., 2019). In T2DM patients, the occurrence of depressive 
symptoms was associated with greater glycemic control. Nevertheless, some aspects have to be considered in 
these findings' interpretation. First, in the current sample, depressive symptoms results showed subclinical 
significance as opposed to the ones identified in previous studies (Braz et al., 2012). More recently, Shrestha et al. 
(2020) conducted a systematic review and found inconsistent results regarding the association between 
subthreshold depression and self-care behaviors in T2DM. Also, it is relevant to note the fact that the significant 
differences between the groups are fundamentally somatic. Considering the symptoms, "work difficulty," 
"insomnia," "fatigability," "weight loss," and "loss of libido" it is hypothesized that these might well correspond to 
the physical consequences of DM as opposed to depressive symptoms. Some authors consider that the 
relationship between depression and DM may be related to other biological changes, namely high cortisol levels 
and changes in norepinephrine and serotonin levels (Talbot et al., 1999; Griffiths & Lustman, 1997). 
Consequently, the relationship between depressive symptoms and glycemic control found in T2DM patients may 
not express this relationship. It may result from the need to adapt to lifestyle changes and the physical 
consequences of DM. These lifestyle changes aiming for the improvement of metabolic control may have 
consequences, and these can be confounded with the previously mentioned BDI symptoms. Thom et al. (2019), in 
their literature review, suggest that major depression may be seen as a systemic illness given that its 
pathophysiology overlaps with other systemic medical conditions. 
Furthermore, these results may also be interpreted from an evolutionary perspective. Mood plays a mediating 
role regarding the mobilization of survival strategies, and negative mood states may lead to the activation of 
psycho-emotional resources when facing demanding tasks (Rottenberg, 2014). Therefore, it is hypothesized that 
T2DM patients showing higher levels of depressive symptoms may be prone to pursue therapy and consequently 
improve their glycemic control. The relationship between DM and depression can be explained by disease 
management factors (Mezuk et al., 2013), and the identification and treatment of depression in DM patients are 
also highly recommended (Khan et al., 2019; Owens-Gary et al., 2019). 
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The BDI is considered as an adequate instrument for assessing depression in T1DM and T2DM patients (Lustman 
et al., 1997). However, it is a general instrument and may not address specificities inherent to DM. Furthermore, 
the BDI is a self-report measure, and this can be a limitation given that more detailed information can be obtained 
via a structured interview. In this context, the development of an assessment instrument able to capture the 
emotional impact of DM specific features would be relevant in the future. Other limitations to be acknowledged 
are the study's cross-sectional design that does not allow causal conclusions to be drawn and the sample size. 
Additionally, the study examines different size groups of DM patients who have sought support at the APDP, and 
it can be theorized that the contact with a patients' association may contribute to being better informed and more 
integrated and, consequently, presenting lower levels of depressive symptomatology. There are therapeutic 
factors that operate as change promoters in group contexts, as would be the case of patients' associations that 
support individuals with the disease (Yalom & Leszcz, 2005). Nevertheless, additional research is needed to clarify 
the role of being in touch with a patients' association in depressive symptoms and glycemic control. 
 
Conclusion 
To sum, it is important to highlight the distinction between depressive symptoms and the physical consequences 
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